Hydroxyethyl starch 130/0.4
ApprovedSmall molecule
Hydroxyethyl starch 130/0.4 is one of 26 small molecule programs targeting Complication. It is currently in Approved.
2
Indications
5
Total Trials
2
Active Trials
25
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
136 competitors in Hypotension
#DrugCompanyPhaseTrials
1Levophed
GGeneral Hospital of Ningxia Medical University
Phase 3
Firazyr
TakedaPhase 3
Cortef
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Midodrine Hydrochloride
TakedaPhase 3
Precose
BayerPhase 2
Noradrenaline
IInstitute of Liver and Biliary Sciences, India
Phase 3
L-Carnitine
IIperboreal Pharma Srl
Phase 3
Hydroxyethyl starch 130/0.4
FFresenius
Approved
Bronitin Mist
LLongeveron Inc.
Phase 3
Voluven
RRegional Hospital Holstebro
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
High Cardiovascular Risk1 trial
Cardiopulmonary Bypass1 trial
Anesthesia Induction1 trial
Crystalloid vs Colloid for Hemodynamics During Anesthesia Induction in TAVR Patients
Not yet recruiting·—·N/A·NCT07329660·116 enrolled
Complication1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Hydroxyethyl starch 130/0.4. EMBL-EBI & Wellcome Sanger Institute.
- [4]